The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: A prospective analysis from the ECLIPSE study

The Lancet Respiratory Medicine

Volumn 1, Issue 2, 2013, Pages 129-136

  Coxson, Harvey O ^a   Dirksen, Asger ^b   Edwards, Lisa D ^c   Yates, Julie C ^c   Agusti, Alvar ^d   Bakke, Per ^e   Calverley, Peter MA ^f   Celli, Bartolome ^g   Crim, Courtney ^c   Duvoix, Annelyse ^h   Fauerbach, Paola Nasute ^a   Lomas, David A ^h   Macnee, William ⁱ   Mayer, Ruth J ^c   Miller, Bruce E ^c   Müller, Nestor L ^a   Rennard, Stephen I ^j   Silverman, Edwin K ^g   Tal Singer, Ruth ^c   Wouters, Emiel FM ^k   Vestbo, Jørgen ^l,m   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITY OF BERGEN   (Norway)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

^j UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^k MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^l ODENSE UNIVERSITY HOSPITAL   (Denmark)

^m UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; FIBRINOGEN; INTERLEUKIN 6; SURFACTANT PROTEIN D;

ADULT; ARTICLE; BODY MASS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DENSITY; LUNG EMPHYSEMA; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RESPIRATORY AIRFLOW; SEX DIFFERENCE; SMOKING;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; EMPHYSEMA; FEMALE; HUMANS; INFLAMMATION; LOGISTIC MODELS; LONGITUDINAL STUDIES; LUNG; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; PULMONARY VENTILATION; RECEPTORS, IMMUNOLOGIC; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SMOKING; SMOKING CESSATION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84878642324     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70006-7     Document Type: Article

References (39)

1. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011, 365:1184-1192.
2. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease Global Initiative for Chronic Obstructive Lung Disease, (accessed May 8, 2011). http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=2180.
3. Hogg JC, Wright JL, Wiggs BR, Coxson HO, Saez AO, Pare PD Lung structure and function in cigarette smokers. Thorax 1994, 49:473-478.
4. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653.
5. McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 2011, 365:1567-1575.
6. Madani A, Zanen J, de Maertelaer V, Gevenois PA Pulmonary emphysema: objective quantification at multi-detector row CT-comparison with macroscopic and microscopic morphometry. Radiology 2006, 238:1036-1043.
7. Müller NL, Staples CA, Miller RR, Abboud RT " Density mask" An objective method to quantitate emphysema using computed tomography. Chest 1988, 94:782-787.
8. Gietema HA, Muller NL, Fauerbach PV, et al. Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort. Acad Radiol 2011, 18:661-671.
9. Han MK, Kazerooni EA, Lynch DA, et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes lung volumes and emphysema in smokers with interstitial lung abnormalities. Radiology 2011, 261:274-282.
10. Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:44-52.
11. 1 in smokers using quantitative computed tomography. Thorax 2009, 64:944-949.
12. 1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999, 160:1468-1472.
13. Stolk J, Putter H, Bakker EM, et al. Progression parameters for emphysema: a clinical investigation. Respir Med 2007, 101:1924-1930.
14. 1-antitrypsin deficiency. Eur Respir J 2009, 33:1345-1353.
15. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010, 11:122.
16. Patel BD, Coxson HO, Pillai SG, et al. Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 178:500-505.
17. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 2008, 31:869-873.
18. Ashraf H, Lo P, Shaker SB, et al. Short-term effect of changes in smoking behaviour on emphysema quantification by CT. Thorax 2011, 66:55-60.
19. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
20. Hedlund LW, Vock P, Effmann EL Computed tomography of the lung. Densitometric studies. Radiol Clin North Am 1983, 21:775-788.
21. Dirksen A Monitoring the progress of emphysema by repeat computed tomography scans with focus on noise reduction. Proc Am Thorac Soc 2008, 5:925-928.
22. Lomas DA, Silverman EK, Edwards LD, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009, 34:95-102.
23. Lomas DA, Silverman EK, Edwards LD, Miller BE, Coxson HO, Tal-Singer R Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 2008, 63:1058-1063.
24. Sin DD, Miller BE, Duvoix A, et al. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 183:1187-1192.
25. Dickens JA, Miller BE, Edwards LD, et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011, 12:146.
26. Efron B, Tibshirani R An introduction to the bootstrap 1993, Chapman and Hall, New York.
27. Hoesein FA, Zanen P, Gietema HA, Lammers JW CT-quantified emphysema in heavy smokers. Severity of emphysema is associated with lung function decline. Ned Tijdschr Geneeskd 2011, 155:A3751.
28. Shaker SB, Dirksen A, Lo P, Skovgaard LT, de Bruijne M, Pedersen JH Factors influencing the decline in lung density in a Danish lung cancer screening cohort. Eur Respir J 2012, 40:1142-1148.
29. Kishore U, Greenhough TJ, Waters P, et al. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol 2006, 43:1293-1315.
30. Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, et al. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE. Eur J Heart Fail 2010, 12:1092-1100.
31. Miniati M, Monti S, Bastac G, Cocci F, Fornai E, Bottai M Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res 2011, 12:37.
32. Cheng DT, Belousov A, Cockayne DA, et al. Plasma proteomic profiling of baseline biomarkers associated with high resolution CT (HRCT) in the TESRA cohort. Am J Respir Crit Care Med 2012, 185:A4509.
33. Kong X, Cho MH, Anderson W, et al. Genome-wide association study identifies BICD1 as a susceptibility gene for emphysema. Am J Respir Crit Care Med 2011, 183:43-49.
34. Kim DK, Hersh CP, Washko GR, et al. Epidemiology, radiology, and genetics of nicotine dependence in COPD. Respir Res 2011, 12:9.
35. Kim WJ, Hoffman E, Reilly J, et al. Association of COPD candidate genes with computed tomography emphysema and airway phenotypes in severe COPD. Eur Respir J 2011, 37:39-43.
36. Sorheim IC, DeMeo DL, Washko G, et al. Polymorphisms in the superoxide dismutase-3 gene are associated with emphysema in COPD. COPD 2010, 7:262-268.
37. DeMeo DL, Hersh CP, Hoffman EA, et al. Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med 2007, 176:42-48.
38. Fletcher C, Peto R The natural history of chronic airflow obstruction. Br Med J 1977, 1:1645-1648.
39. Vestbo J, Anderson JA, Calverley PM, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J 2011, 5:44-49.